ABSTRACT: Neurofibromatosis type 1 (NF1) was first described in 1882 and is characterized by a diverse spectrum of clinical manifestations, including neurofibromas, cafe au lait spots, and Lisch nodules. NF1 is also noted for the higher risk of associated malignancies, making it the most common tumour-predisposing disease in humans. Transmitted in an autosomal dominant manner, the NFI gene was cloned in 1990, and belongs to the family of tumour suppressor genes. Since then, there has been an explosion in our understanding of how the gene product, neurofibromin, functions in normal cellular physiology, and how its loss in NF1 relates to the wide spectrum of clinical findings, including NF1-associated tumours. Neurofibromin is a major negative regulator of a key signal transduction pathway in cells, the Ras pathway, which transmits mitogenic signals to the nucleus. Loss of neurofibromin leads to increased levels of activated Ras (bound to GTP), and thus increased downstream mitogenic signaling. Our understanding of neurofibromin's role within cells has allowed for the development of pharmacological therapies which target the specific molecular abnormalities in NF1 tumours. These include the farnesyl transferase inhibitors, which inhibit the post-translational modification of Ras, and other agents which modulate Ras-mediated signaling pathways. RESUME: Neurofibromatose de type I: la solution de l'enigme. La neurofibromatose de type I (NFI) a etfi decrite pour la premiere fois en 1882. Elle se caracterise par un spectre varie de manifestations cliniques incluant des neurofibromes, des taches cafe au lait et des nodules de Lisch. On sait aussi que la NFI confere un risque plus elevd de cancers associes, ce qui en fait la maladie la plus frequente associee a une predisposition tumorale chez l'humain. Le gene de la NFI, clond en 1990, est transmis sur le mode autosomal dominant et fait partie de la famille des genes suppresseurs de tumeurs. Depuis ce temps, il y a eu une explosion dans notre comprehension de la facon dont le produit du gene, la neurofibromine, fonctionne dans les cellules physiologiquement normales et comment son absence dans la NFI mene a un large spectre de manifestations cliniques dont les tumeurs associees a la NFI. La neurofibromine est un regulateur negatif important d'une voie de transduction d'un signal eld dans les cellules, la voie Ras, qui transmet des signaux mitogenes au noyau. Le deficit en neurofibromine provoque des niveaux eleves de Ras active (lie au GTP) et done une augmentation du signal mitogene en aval. Notre comprehension du role de la neurofibromine dans les cellules a mene au deVeloppement de traitements pharmacologiques qui ciblent les anomalies moleculaires specifiques aux tumeurs NFI. Parmi ceux-ci, signalons les inhibiteurs de la farnesyl transferase qui inhibent la modification post-traductionnelle de Ras et les autres agents qui modulent les voies de signalisation mediees par Ras.
THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
The hallmarks of NFl are the cutaneous neurofibromas, consisting of a mixture of Schwann cells, fibroblasts, and mast cells, 7 which generally do not appear until adolescence. Therefore, other defining features arising earlier in childhood are often the first signs of NFl. These include CAL, which appear during the first year of life and are present in 95% of NFl adults. 8 Since 3 CAL spots may be present in up to 25% of the normal population, 9 6 or more CAL spots is considered suggestive of NFl . l0 Freckling in non-sun-exposed regions of the body and Lisch nodules (pigmented hamartomas of melanocytic origin in the iris) are more specific and can be detected early in NFl patients. 8 " While these are the most common clinical signs of NFl, a large number of diverse cutaneous, osseous, hematologic, developmental, and nervous system abnormalities are often present. 2 The number and severity of these clinical abnormalities is variable not only between members of different NFl families, but between members of the same family, leading to occasional confusion in the clinical diagnosis. In an effort to standardize diagnostic criteria, which has tremendously helped both epidemiological and molecular studies on NFl, the National Institutes of Health set uniform diagnostic criteria for NFl, as well as a separate set of criteria for NF2 10 (Table) . Despite recent advances in our understanding of the molecular basis of NFl, these clinical criteria continue to be the most reliable means for making the diagnosis. 12 The two major life threatening complications of NFl are hypertension and cancer. 1 3 1 4 Renal artery stenosis and pheochromocytoma, which occur at a higher frequency in NFl patients, should be excluded as the cause for hypertension, although most hypertension is primary in nature. 15 Malignancies other than neurofibromas and pheochromocytomas noted at a higher frequency in NFl patients include malignant peripheral nerve sheath tumours (MPNST), astrocytomas (most notably optic gliomas), and chronic myeloid leukemias of childhood. 16 In contrast, common adult malignancies such as lung, colon and breast cancers are not seen at higher frequency in NFl. 17 Most NFl-related deaths are thus attributed to either hypertension or cancer. In a 12-year prospective population study in Gbteborg, Sweden, 22 of 70 NFl patients died, 10 from hypertension and 12 from malignancies.
14 These NFl patients thus demonstrated an age and sex-adjusted death rate 4.3 times that of the non-NFl Swedish population. Nonetheless, the diagnosis of NFl should not be routinely regarded as life threatening, with a majority of patients surviving well into their adulthood, with a mean survival age of 61.6 years in this study. 14 
Genetics
NFl has a birth incidence of 1:2500-1:3000, with a prevalence of 1:4000-1:5000. 18 The Mendelian inheritance pattern of NFl is autosomal dominant. 19 " 21 Although case reports have suggested that NFl can skip generations, these cases likely represent mildly affected individuals. 22 About 30-50% of NFl patients represent de-novo germline mutations, 220 implying an extremely high spontaneous mutation rate of the NFl gene. This mutation rate has been estimated at 1 mutation per 10,000 alleles per generation, a rate 10-100 times higher than the usual mutation rate for a single locus.
2023, 24 Such a high mutation rate may be related to the large size of the NFl gene, as the similarly large Duchenne muscular dystrophy (DMD) gene 25 also demonstrates a mutation rate of 1/10,000 alleles/generation. 26 Howev- The diagnostic criteria of the National Institutes of Health Consensus Conference on Neurofibromatosis (July, 1987) are met by an individual who demonstrates two or more of the following:
• 6 or more cafe au lait macules of over 5 mm in greatest diameter in prepubertal individuals and over 15 mm in greatest diameter in postpubertal individuals
• 2 or more neurofibromas of any type or one plexiform neurofibroma
• axillary or inguinal freckling
• optic glioma
• 2 or more Lisch nodules (iris hamartomas of melanotic origin)
• a distinctive osseous lesion such as sphenoid dysplasia or thinning of the long bone cortex with or without pseudoarthrosis
• a first-degree relative (parent, sibling, or offspring) with NFl by the above criteria.
er, the size of the gene may not be the full explanation, as evidenced by a similar germ-line mutation rate of the much smaller NF2 gene, which has a ten-fold lower birth incidence than NFl (1/33,000-40,000 live births). 5 Germ-line mutations of the NFl gene occur preferentially on the paternally-derived allele, 26 " 29 which has also been noted in achondroplasia, Lesch-Nyhan syndrome, and hemophilia A. However, in each of the latter diseases the incidence of new mutations increases with parental age, 29 implying that paternal bias is related to the high number of cell divisions which occurs during spermatogenesis, 26 -29 a pattern not seen in NFl. 2 2 9 The phenomenon of genomic imprinting has been proposed as an alternate explanation for these preferential paternal allele mutations. 27 " 31 Classical Mendelian genetics assumes that both alleles (maternal and paternal) of a gene participate equally in determining the phenotype of the offspring. The concept of genomic imprinting has thus been developed to explain situations where one allele is preferentially expressed over the other allele. Hence, genomic imprinting is an epigenetic phenomenon, in which non-genetic modifications of an allele result in altered expression and phenotype. A common mechanism resulting in genomic imprinting involves hypermethylation of the sperm genome; 3233 a hypermethylated gene is at higher risk for mutations through the spontaneous deamination of 5-methylcytosine (methylated cytosine nucleotides) to thymine. 30 Methylation has also been proposed as a mechanism for gene silencing, in which either the maternally-or paternallyderived allele is active while the other allele does not contribute to gene expression. Methylation may thus explain why children of affected NFl mothers (mutation of the maternal NFl allele with gene silencing of the paternal NFl allele by methylation) often demonstrate a more severe clinical manifestation than children of affected fathers (in which the mutated paternal allele may be silenced by methylation, allowing the non-mutated maternal allele to alone contribute to gene expression). 34 In addition to the NFl allele, some evidence exists that other genetic loci may also contribute to the phenotype of NFl patients. Analyses of monozygotic twins and more distantlyrelated family members with NFl demonstrate that monozygotic twins have very similar phenotypes, while non-twin siblings and more distantly-related family members (who presumably carry identical NF1 mutations) frequently exhibit very different phenotypes. 35 Such a pattern is suggestive of polygenic inheritance, and implies that the expression or mutation of non-NFJ alleles is important in determining the phenotype of NF1 patients. 35 
Cloning the NF1 gene
The uniform NIH clinical diagnostic criteria led to the identification of a relatively homogenous cohort of patients and families with NF1,'° which in turn played a pivotal role in the ultimate identification of the responsible gene. Restriction fragment length polymorphism (RFLP) and linkage studies of NF1 families suggested the pericentromeric region of chromosome 17 as the likeliest site for the NF1 gene.
3639 Two NF1 families with balanced translocations involving 17q (t(l;17) and t(17;22)), 40 Mutations of the first candidate gene, EV12A, the human homologue of a mouse gene implicated in retrovirus-induced murine myeloid tumours, were not found in any NF1 patients, thus ruling it out. 44 The second candidate gene was EV12B, also a human homologue of a murine gene implicated in retroviral insertions, however, it also failed to demonstrate mutations in NF1 patients. 45 The OMGP gene, encoding oligodendrocytemyelin glycoprotein and expressed only in oligodendrocytes and Schwann cells, was the third candidate gene, 46 but also was found not to be mutated in NF1 patients. Subsequent analysis has shown that these three genes are encoded within the large authentic NF] gene, 47 but transcribed off the opposite strand, a phenomenon known as "nested genes". The contribution of these three nested genes to the NF1 clinical phenotype, if any, is not known. Due to the evolution of the exon numbering scheme, the exon containing the 3' stop codon is numbered exon 49, even though the entire gene consists of 59 exons. 50 The second-largest intron is intron 27b (45-50 kb), which contains the three nested genes OMPG, EVJ2A, and EVJ2B described above. 50 Exons 21-27a encode a 360 amino acid domain in the protein product which demonstrates homology with GTPase-activating proteins, and is termed the GAP-related domain (GRD). 50 The 5' promoter region contains a cAMP response element (CRE), AP2 consensus binding sites, and a serum response element (SRE). 5 ' The cDNA is 8454 nucleotide base pairs (bp) in length, 18 with two messenger RNA (mRNA) transcripts (11 and 13 kb), which differ in the length of their 3' untranslated region. 50 -52 Expression of neurofibromin Neurofibromin is composed of 2818 amino acids with a molecular weight of 220 kilo-Daltons (kDa).
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- 54 While NF] mRNA is detectable in most tissues, the expression of the neurofibromin protein is more tightly regulated, with highest levels found in neurons, oligodendrocytes, non-myelinated Schwann cells, adrenal medulla, leukocytes and testis. 5556 In comparison, it is expressed in low amounts in adult astrocytes, myelinated Schwann cells, lung and kidney. 55 -56 Four neurofibromin isoforms, which differ in their developmental and tissue expression, have been identified due to insertions into exons 23a, 48a, and 9a ( Figure 1 ). Type 1 neurofibromin was the original isoform isolated and lacks any of these insertions. Type 2 isoform has an insertion of 63 nucleotides (21 amino acids) in exon 23a within the NF1-GRD, 57 -58 which results in a 10-fold lower Ras-GAP activity and lower tubulin binding capacity. 56 -57 Type 1 neurofibromin is the predominant isoform expressed in neurons of the CNS (cerebellum, cerebral hemispheres, and brainstem) and dorsal root ganglia, while the Type 2 isoform is predominantly expressed in tissues derived from the neural crest such as Schwann cells and adrenal medullary cells, in addition to glia and anterior horn cells of the adult spinal cord.
Its cloning in 1990 was facilitated by the discovery of two NF1 patients with balanced translocations involving chromosome 17q (t(l;17) and t(17;22)). Three attempts at identifying the
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Insertion of 54 nucleotides (18 amino acids) in exon 48a near the extreme carboxyl terminus results in the Type 3 isoform, 60 which is almost exclusively expressed in skeletal, cardiac, and smooth muscle, with little or no expression in brain, spleen or kidney. 61 This isoform is highly expressed during embryogenesis and declines shortly after birth, suggesting a role in muscle development. 61 Insertion of 30 nucleotides (10 amino acids) in exon 9a, within the NFl-GRD yields the Type 4 isoform, which is only expressed in neurons of the CNS, and not in neural crest derived tissues 62 or in glial cells. 63 Within the CNS, there is regional variation in the expression of the Type 4 isoform, which also likely plays a role in neuronal development, with increased expression during late embryogenesis. 63 In addition, this isoform is highly expressed in medulloblastomas and oligodendrogliomas, while it is found in low levels in astrocytomas, meningiomas, and ependymomas. Ras is a 21 kDa intracellular protein that is involved in the transmission of signals from a variety of upstream activators such as growth factor receptors, to a large number of downstream signaling molecules which eventually alter gene function in the nucleus. Ras is a member of the small G protein family, characterized by being bound to GDP in the basal inactive state, and being activated to the GTP bound state by guanine nucleotide exchange factors, in particular Sos.
69 -70 - [75] [76] [77] [78] [79] As schematized in Figure 2 , activated growth factors such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) bind and activate their cognate receptor, with receptor activation characterized by autophosphorylation of specific tyrosine residues on the intracellular domain of the receptor. Specific phosphotyrosine residues on the activated receptor are recognized by protein modules, such as SH2 (src homology-2) and PTB (Phosphotyrosine Binding) domains, on intracellular signaling proteins such as Grb2 and She. 75 -80 ' 81 Grb2 and She, through their interactions with the activated receptors in turn recruit other proteins such as Sos to the receptor in proximity to its substrate (inactive Ras'GDP) at the cell surface. 76 Sos exchanges Ras-bound GDP for GTP, resulting in activation of Ras and initiation of downstream signaling pathways, in particular the mitogenic cascade through Raf, MAPKK (mitogen-activated protein kinase kinase, also known as MEK or ERK kinase), and MAPK (mitogen-activated protein kinase, also known as extracellular signal related kinase or ERK) (Figure 2 ).
The importance of activation of the Ras pathway and subsequently Raf-MAPKK-MAPK leading to mitogenic signals, is exemplified by oncogenic activating mutations of Ras being found in approximately 30% of all human cancers. 71 -8283 In addition to oncogenic mutations, functional up-regulation of the Ras pathway can also be achieved by increased stimulation from upstream activators of Ras (i.e., signals from activated receptors) or decreased inhibitors of the Ras pathway. With regards to the latter mechanism, activated Ras'GTP is slowly hydrolyzed to GDP by intrinsic GTPase activity in native Ras, a process that is rapidly catalyzed by Ras-GAPs, including neurofibromin. 47 - [67] [68] [69] [70] [71] [72] [73] [74] Several pieces of evidence demonstrate that neurofibromin is an important mammalian Ras-GAP, other than the homology of the GRD domain with other known Ras-GAPs (reviewed above): 1) Expression of only the N F l -G R D portion is capable of hydrolyzing Ras'GTP to Ras'GDP in vitro M and in vivo. iS 2) Expression of the NFl-GRD is able to rescue Iral and Ira2 deficient yeast mutants. 86 3) Overexpression of neurofibromin or the GRD portion suppresses oncogenic Ras transformed cells. [87] [88] [89] [90] [91] Another pivotal discovery that supported the Ras-GAP function of neurofibromin was the demonstration that neurofibrosarcoma (malignant peripheral nerve sheath tumour) cell lines established from NF1 patients not only lacked neurofibromin expression but had elevated levels of activated Ras'GTP. 88 - 89 We have recently adapted a luciferase-based enzymatic assay to quantitate the levels of Ras'GTP in actual tissue specimens from NF1 patients. We have confirmed that in NF1-associated malignant peripheral nerve sheath tumours (MPNST), neurofibromin expression is absent and that levels of Ras'GTP are substantially elevated. 73 Our studies demonstrate that Ras'GTP levels are approximately four and fifteen times higher in NF1-associated neurofibromas and MPNSTs respectively, compared to schwannomas from non-NFl patients.
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Neurofibromin function: additional functions
While it is clear that neurofibromin acts as a Ras-GAP, there is also a growing body of evidence that this is not its only function. First, in melanoma and neuroblastoma cell lines levels of activated Ras'GTP are not elevated, despite complete absence of neurofibromin. 93 Second, overexpression of neurofibromin in Ras transformed cells revert the tumourigenic phenotype, even though the oncogenic Ras mutant is insensitive to neurofibromin's GTPase activity. 90 Since oncogenic Ras mutants, like normal Ras, can bind neurofibromin (through interactions with the NFl-GRD region) but are resistant to its Ras-GAP activity, it would suggest that in addition to its Ras-GAP role neurofibromin has other tumour suppressor functions. In fact, overexpression of just the NFl-GRD region in these /?as-transformed cells is equally successful in reverting the malignant phenotype. 94 It is not clear what these non Ras-GAP related tumour suppressor functions of neurofibromin entail. Neurofibromin does associate with microtubules, 95 " 97 suggesting a potential role in linking activated Ras'GTP to changes in cellular structure. Additional functions may relate to neurofibromin's six potential serine/threonine cAMP dependent protein kinase recognition sites and one potential tyrosine phosphorylation site, which are phosphorylated in response to PDGF or EGF. Phosphorylation of these residues however has no effect on neurofibromin's Ras-GAP activity. 100 The presence of phosphorylation sites as well as neurofibromin's interactions with the cytoskeleton suggest that it is a highly regulated protein. We have investigated how activation of Ras might affect the expression of neurofibromin, and demonstrated that activated Ras'GTP transcriptionally upregulates neurofibromin expression. 101 For instance, human malignant astrocytoma cell lines have increased levels of Ras'GTP due to stimulation from growth factor receptors (A. Guha, unpublished results), with abundant neurofibromin expression. Inhibiting Ras'GTP levels in these cells, using dominant negative Ras mutants, reduced NF1 mRNA and protein
Figure 2: Schematic representation of the Ras-Raf-MAPK mitogenic signaling pathway. This cascade is activated in normal cells when ligand (a growth factor such as platelet-derived growth factor) hinds its cognate surface receptor (STEP 1). Ligand:receptor interaction results in receptor dimerization (STEP 2), resulting in transautophosphorylation of tyrosine residues on the intracellular domain of the receptor (STEP 3). This allows signaling molecules with SH2 domains (She, Grb2 or the Shc:Grb2 complex) to interact with the phosphotyrosine residues, bringing the nucleotide exchange factor Sos in proximity to the cell surface, where it exchanges GDP with GTP, activating Ras. Raf interacts with activated Ras'GTP, phosphorylating MAPKK, which subsequently phosphorylates MAPK. MAPK translocates to the nucleus where it participates with other molecules in activating the transcription of the transcription factors fos and jun, resulting in the increased transcription of genes involved in cell division and other functions (STEP 4).
expression. 101 Neurofibromin expression is also increased in reactive astrocytes surrounding regions of focal ischemia, 102 and in juvenile pilocytic astrocytomas. 54 These results suggest a physiological negative feedback response, whereby activation of the Ras pathway increases neurofibromin expression in order to downregulate the Ras pathway.
Neurofibromin as a tumour suppressor gene
The concept of the "two hit" hypothesis in tumour suppressor genes (TSG) in familial cancer syndromes developed from the work of Knudson in the molecular pathogenesis of retinoblastoma. 103 The first hit involves a germ-line loss of function in one LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES allele present in all cells, with the second hit being a somatic loss of function of the remaining allele in selected cells leading to tumour formation. NF1 patients bear a germ-line loss of function in one NF1 allele which is either inherited or a de-novo mutation as previously discussed, with loss of function in the second allele resulting in complete absence of neurofibromin expression and the genesis of tumours. There is evidence that this model holds true for a variety of NF1-associated tumours, including benign neurofibromas, 28 NFJ +/-mice possess a single functional NFJ allele. 109 While the classical cutaneous and ocular features of NF1 were not detected, 75% of these mice succumbed to tumours compared to 15% in a matched set of wild type animals. Many of the tumours encountered (such as lymphoma) are tumours often seen in older wild-type mice, but in the heterozygous knockout mice these tumours appeared earlier and at a higher frequency. Other tumours identified in the heterozygous mice (particularly pheochromocytoma and myeloid leukemia) are rare in wild-type animals, but are characteristic tumours found at higher frequency in NF1 patients. It is significant to note that all NFl-like tumours (pheochromocytomas and myeloid leukemias) in the mice demonstrated loss of the second NFJ allele, consistent with the Knudson hypothesis. 109 The importance of neurofibromin in cellular growth and differentiation was exemplified by the homozygous NF1 -I-knockout mice, which are embryonically lethal between days 12.5 and 14 of gestation. 109 " 0 Surprisingly, the cause of death in all embryos examined was severe cardiac vessel developmental anomalies, notably a double outlet right ventricle in which the aorta and pulmonary artery are joined, which is not a characteristic feature of NF1 patients. 109 The cardiac anomalies are however not surprising, as neural crest-derived cells contribute to the development of the great vessels."
1 Additional anomalies discovered in some of these homozygous knockout embryos include liver and skeletal muscle hypoplasia (consistent with the proposed role for exon 48a-containing neurofibromin isoforms in muscle development), delayed renal development, hyperplasia of the prevertebral and paravertebral sympathetic ganglia, as well as hyperplasia of the cells lining the aorta and pulmonary artery.
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The creation of NFJ -I-knockout mice 109 " 0 has been exploited in gaining further insights into the functions of neurofibromin. Sensory neurons of the trigeminal and dorsal root ganglia derived from wild-type mouse embryos are dependent on the neurotrophic factor nerve growth factor (NGF) for survival, while nodose ganglion sensory neurons are dependent on brain-derived growth factor (BDNF) for their survival in cell culture. Sensory cells derived from NF1 -I-embryos on the other hand are capable of surviving and extending neuronal processes in the absence of NGF or BDNF." 2 This extends previous studies in which activated Ras'GTP was able to mimic the survival-promoting effects of neurotrophic factors," 3 and identifies neurofibromin as a major regulator of neurotrophin-and Rasmediated neuronal survival. 112 Studies on NF1 -I-Schwann cells confirmed that neurofibromin is a major negative regulator of Ras in these cells, as they demonstrate elevated levels of Ras'GTP. 114 Furthermore, these Schwann cells take on morphological characteristics of Ras transformed cells, and are similar to Schwann cells stimulated with trophic factors such as the neuregulins, which activate the Ras pathway through activation of their receptors." 4 " 5 In contrast to Schwann cells, fibroblasts from the NF1 -/-mice did not demonstrate elevated levels of Ras'GTP, in support of other experimental data previously discussed that the importance of neurofibromin as a Ras-GAP differs between cell types, with perhaps Ras activity in some cells predominantly regulated by other Ras-GAPs such as pl20-GAP. 114 
Malignant transformation of neurofibromas in NF1 patients
Benign neurofibromas consist of a heterogeneous population of Schwann cells, mast cells, fibroblasts, neuronal axons, perineural cells and endothelial cells. 2 " 6 The dermal neurofibromas are generally little more than a cosmetic problem while the larger plexiform neurofibromas, though histologically benign, arise in nerve plexuses and present with neurological deficits. Of greater significance, the plexiform neurofibromas have a 3-4.6% risk for malignant transformation, 13117 a figure much lower than previously speculated, but one which is much higher than the less than 1% risk of malignant transformation in a non-NFl neurofibroma."
8 " 9 Knowledge of these risks for malignant transformation vs. the surgical risks have to be considered for the proper management of NF1 patients presenting with peripheral nerve tumours.
Although activating mutations of Ras are not found in benign or malignant peripheral nerve tumours, several other TSGs have been implicated in the pathogenesis of MPNSTs (Figure 3) . Loss or mutations of the p53 gene on chromosome 17p has been discovered in numerous sporadic and NF1-associated MPNSTs. 120125 Mutations of the retinoblastoma (Rb) gene, found in osteosarcomas, appear not to play a role in the pathogenesis of MPNSTs.
"
128 Cytogenetic analysis suggests that hotspots for additional mutations in NFl-associated MPNSTs are located on chromosomes 1, 11, 12, 14, and 22. 129 Microsatellite instability (MI), which represents expansions or compressions of di-, tri-, or tetra-nucleotide repeats in a genetic locus, are a frequent finding in NFl-associated neurofibromas, with 8/16 patients manifesting alterations at one or more microsatellite loci within the tumour. 130 However, the definition of what is significant MI is evolving, with the current accepted criterion requiring involvement of at least two or more loci. 131 When this more stringent criterion is applied to NFl-associated MPNSTs, only 1/16 patients truly demonstrates MI.
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Applying our understanding of molecular biology to improving the diagnosis of NF1
Despite the identification of the NF1 gene, it has been difficult to apply genetic techniques to the diagnosis of NFL NF1 patients frequently request prenatal genetic testing to rule out transmission of the defective NF1 gene to their child. Similarly, NF1 patients who do not desire prenatal testing may still wish to screen their young child for the defective allele, as many phenotypic manifestations of NF1 do not appear until late childhood or early adolescence. Both of these situations lend themselves well to genetic testing, provided that the family NFJ mutation is known. As the child can be expected to carry the same mutation as the affected parent, genetic testing can be very focussed and specific. In situations where the NFJ mutation has not been characterized, genetic testing would imply a far more general screening of the entire gene. Such testing would thus be identical to genetic screening techniques applied to patients without a family history of NFL A large variety of mutations have been discovered in the NF1 gene in NF1 patients, including single base mutations, deletions of various sizes including the entire gene, insertions, splicing errors, and translocations. 50133 Only one mutation has been found to be relatively common in NF1 patients, but this R1947X mutation still only accounts for at most 8% of mutations among Japanese patients and at most 2% of NFJ mutations among Caucasians. 134 Hence, no single specific alteration in high frequency (mutational hotspot) or significant genotype-phenotype correlation (where one can predict the clinical presentation based on the location and type of mutation) has been identified. 133 The lack of mutational hot spots, large size of the NFl gene, high spontaneous mutation rate and lack of genotype-phenotype correlation have all contributed to the hurdles which still make routine genetic screening impractical.
12135 " 137 The NIH clinical diagnostic criteria remains the best method of detecting new patients with NFl (see Table) .
Applying our understanding of molecular biology to improving the clinical management of NFl
Although our understanding of the molecular events in NFl have not displaced the NIH clinical criteria in making the diagnosis of NFl (see Table) , our expanding understanding of these molecular events has resulted in new efforts to treat the variety of symptoms and tumours associated with this syndrome. Surgery is not always an option for deep-seated tumours or in eloquent regions of the central or peripheral nervous system. Even when surgery is performed, patients with M P N S T frequently succumb not to their primary tumour but to metastases (L. Angelov, R. Bell, and A. Guha, unpublished observations), and all patients dying of malignancy in the Swedish prospective study harboured metastases at the time of death.
14 In particular, the pivotal role that neurofibromin plays in the regulation of the Ras pathway suggests that novel pharmacological inhibitors of Ras pathway activators may hold great promise for managing a number of NFl-associated benign or malignant lesions.
Ras pathway activation has been implicated in 30% of human malignancies, on the basis of oncogenic point mutations in /fas. 71 ' 82 - 83 Many pharmaceutical companies and academic research groups have thus developed inhibitors of Ras or of proteins in the Ras-Raf-MAPK pathway. In particular, farnesyl transferase inhibitors (FTIs) have been developed which inhibit LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES the first critical step (farnesylation) in the post-translational modification of Ras, a step which is vital for Ras to be recruited to the inner cell membrane where it may be activated. 138 This post-translational modification is catalyzed by the enzyme farnesyl transferase (FTase), and involves the transfer of a 15-carbon trans, trans-famesy\ moiety from farnesyl pyrophosphate (FPP) to the cysteine residue on the CAAX (C = cysteine, A = aliphatic amino acid, X = other amino acid) motif at the C-terminal of Ras. This first step is absolutely essential for Ras to become activated within the cell, while subsequent steps are not critical 139 ( Figure 4 ). Although many other cellular proteins in addition to Ras are farnesylated, no adverse effects have been noted in experimental use of these agents in cell culture and animal models of human tumours bearing oncogenic Ras mutations. 140 However, most studies to date have involved models of human cancer in which oncogenic Ras mutations resulted in constitutive activation of Ras, as demonstrated by elevated levels of Ras'GTP. NFl patients do not harbour oncogenic mutations of Ras, and yet the downregulation of activated Ras'GTP through hydrolysis of GTP to GDP is slowed in the absence of neurofibromin. We had thus hypothesized that Ras*GTP levels would be elevated in MPNSTs in NFl patients. We have confirmed that levels of Ras'GTP are substantially elevated in NFlassociated MPNSTs, 7 3 with R a s ' G T P levels being approximately fifteen times higher in NFl-associated MPNSTs than in non-NFl schwannomas. 7392 Hence, NFl-associated MPNSTs demonstrate activation of the Ras pathway, providing additional evidence to support a beneficial effect of FTIs in the management of NFl. Indeed, FTIs have been shown to inhibit the proliferation of the human MPNST cell line NF188-14 in tissue culture experiments. Additional compounds targeting the Ras pathway are not as well developed presently, but include inhibitors of MEK which is involved in mitogenic signaling downstream of Ras in the RasRaf-MAPK cascade 142 ( Figure 2 ). While such pharmacological manipulations of the Ras pathway are still many years away from routine clinical use, they represent the progress that can be made in clinical treatment based on a solid understanding of basic cellular physiology and of the molecular mechanisms which result in individual disease processes. Future therapy tailored more specifically to the management of NF1 will benefit from further study and understanding of the role that neurofibromin plays in cells, in particular in its non-Ras-GAP functions. Additionally, the clinical management of NF1 will benefit from progress made in our understanding of other aspects of cellular physiology and gene regulation, as activity in a host of other cellular pathways likely impacts on the function of neurofibromin, through positive and negative regulatory loops. We can thus look upon the future with optimism in our goal of developing and implementing novel, effective, and safe therapeutic strategies for NF1.
